Kyle Carver - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: EVMN on NYSE
Reported as of: 07 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Nov 2025, 16:16:43 UTC
Prior SEC filing: 05 Nov 2025
Next SEC filing: 11 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Gregory S. Moss, Attorney-in-Fact

Key filing fact

Kyle Carver filed Form 4 for Evommune, Inc. on 12 Nov 2025.

Key facts

This page summarizes Kyle Carver's Form 4 filing for Evommune, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2025, 16:16.

Change

Previous filing in this sequence was filed on 05 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001757072 Primary reporting owner

Carver Kyle

Relationship: Chief Financial Officer
Address: C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Signature date: 12 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVMN transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +3,175
Change %: +4.4%
Price
Shares after: 75,800
Date: 07 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVMN transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -25,000
Change %: -100%
Price
Shares after: 0
Date: 07 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,175
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.